Literature DB >> 27656839

Knockdown of PARP-1 Inhibits Proliferation and ERK Signals, Increasing Drug Sensitivity in Osteosarcoma U2OS Cells.

Sheng Li1, Zhengli Cui, Xianfeng Meng.   

Abstract

Poly(ADP-ribose) polymerase 1 (PARP-1) is reported to be involved in DNA repair and is now recognized as a key regulator in carcinogenesis. However, the potential role and the molecular mechanism underlying the effect of PARP-1 on osteosarcoma (OS) cells have not been elucidated. In this study, the results showed that knockdown of PARP-1 resulted in decreased cell proliferation, increased cell apoptosis, and G0/G1 phase arrest in U2OS cells. In addition, increased expression of active caspase 3 and Bax, but reduced Bcl-2, cyclin D1, and phosphorylated extracellular signal regulated kinase 1/2 (pERK1/2) were observed in PARP-1 knockdown in U2OS cells. Moreover, knockdown of PARP-1 correlated with elevated chemosensitivity of U2OS cells to cisplatin through inactivation of the ERK1/2 signaling pathway. In conclusion, our findings demonstrated that PARP-1 plays an important role in regulating OS growth, combining PARP-1 gene therapy with traditional chemotherapy, and may serve as a promising approach to OS therapy.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27656839     DOI: 10.3727/096504016X14666990347554

Source DB:  PubMed          Journal:  Oncol Res        ISSN: 0965-0407            Impact factor:   5.574


  8 in total

1.  Evaluation of Utilizing the Distinct Genes as Predictive Biomarkers in Late-Onset Alzheimer's Disease.

Authors:  Sercan Kenanoglu; Nefise Kandemir; Hilal Akalin; Nuriye Gokce; Mehmet F Gol; Murat Gultekin; Emel Koseoglu; Meral Mirza; Munis Dundar
Journal:  Glob Med Genet       Date:  2022-03-08

Review 2.  Soft tissue sarcomas: new opportunity of treatment with PARP inhibitors?

Authors:  Monica Mangoni; Mariangela Sottili; Giulia Salvatore; Domenico Campanacci; Guido Scoccianti; Giovanni Beltrami; Camilla Delli Paoli; Luca Dominici; Virginia Maragna; Emanuela Olmetto; Icro Meattini; Isacco Desideri; Pierluigi Bonomo; Daniela Greto; Lorenzo Livi
Journal:  Radiol Med       Date:  2018-03-26       Impact factor: 3.469

3.  Identification of co-expression modules and pathways correlated with osteosarcoma and its metastasis.

Authors:  Jian-Sheng Wang; Yun-Guo Wang; Yong-Sheng Zhong; Xue-Dong Li; Shi-Xin Du; Peng Xie; Gui-Zhou Zheng; Jing-Ming Han
Journal:  World J Surg Oncol       Date:  2019-03-08       Impact factor: 2.754

4.  PARP-1 overexpression does not protect HaCaT cells from DNA damage induced by SiO2 nanoparticles.

Authors:  Chun-Mei Gong; Yuan-Fei Xu; Xiong-Shun Liang; Jun-Luan Mo; Zhi-Xiong Zhuang
Journal:  Toxicol Res (Camb)       Date:  2021-04-12       Impact factor: 3.524

5.  Targeting Nuclear NAD+ Synthesis Inhibits DNA Repair, Impairs Metabolic Adaptation and Increases Chemosensitivity of U-2OS Osteosarcoma Cells.

Authors:  Alexandra Kiss; Arnold Péter Ráduly; Zsolt Regdon; Zsuzsanna Polgár; Szabolcs Tarapcsák; Isotta Sturniolo; Tarek El-Hamoly; László Virág; Csaba Hegedűs
Journal:  Cancers (Basel)       Date:  2020-05-07       Impact factor: 6.639

6.  ABCA1/ABCB1 Ratio Determines Chemo- and Immune-Sensitivity in Human Osteosarcoma.

Authors:  Dimas Carolina Belisario; Muhlis Akman; Martina Godel; Virginia Campani; Maria Pia Patrizio; Lorena Scotti; Claudia Maria Hattinger; Giuseppe De De Rosa; Massimo Donadelli; Massimo Serra; Joanna Kopecka; Chiara Riganti
Journal:  Cells       Date:  2020-03-06       Impact factor: 6.600

7.  miR‑133b affects cell proliferation, invasion and chemosensitivity in renal cell carcinoma by inhibiting the ERK signaling pathway.

Authors:  Yuan Xu; Yuan Ma; Xiao-Ling Liu; Sheng-Li Gao
Journal:  Mol Med Rep       Date:  2020-05-05       Impact factor: 2.952

8.  Inhibition of SIRT6 potentiates the anti-tumor effect of doxorubicin through suppression of the DNA damage repair pathway in osteosarcoma.

Authors:  Zhongkai Zhang; Sang Hoon Ha; Young Jae Moon; Usama Khamis Hussein; Yiping Song; Kyoung Min Kim; See-Hyoung Park; Ho Sung Park; Byung-Hyun Park; Ae-Ri Ahn; Sang-A Lee; Su Jin Ahn; Jung Ryul Kim; Kyu Yun Jang
Journal:  J Exp Clin Cancer Res       Date:  2020-11-17
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.